跳至主要内容
临床试验/NCT05462652
NCT05462652已完成不适用

Project STAND (Self-guided Treatment for Adolescents Navigating Depression): a Randomized Controlled Trial

Limbix Health, Inc.2 个研究点 分布在 1 个国家目标入组 223 人开始时间: 2022年7月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
223
试验地点
2
主要终点
Depressive Symptom Severity at Post-intervention

研究概览

简要总结

The goal of this study is to test whether an investigational mobile app can be a helpful treatment option for adolescents with symptoms of depression. Adolescents aged 13 to 21 with depression symptoms can be part of this study if eligible.

Eligible participants will be randomly assigned to one of two groups: one group will receive the mobile app intervention in addition to their usual care and the other group will simply continue their usual care for symptoms of depression. Both groups will have 5 weeks to use a study app, and will complete assessments during the intervention period, at post-intervention, and at one month follow-up.

详细描述

The primary aim of the proposed research is to evaluate the effectiveness of a self-guided, cognitive behavioral therapy (CBT)-based mobile app + assessment-enhanced Usual Care (eUC) compared to eUC alone as an intervention for adolescents with symptoms of depression who are under the supervision of a licensed healthcare provider.

The sample size for this study is 220 subjects. Sample size calculation is based on primary outcome patient health questionnaire (PHQ-8) at post-intervention (5 weeks). Six PHQ-8 measurements will be collected from each subject (baseline and weekly during the 5-week intervention period). Using a two-sample t-test approach, assuming a two-tailed alpha set at 0.05, a total of 200 participants (100 in each study arm) will give us 80% power to detect a moderate effect size of at least d=0.4. Given an anticipated 10% rate of attrition, we aim to enroll 220 total participants in the study.

A 50% female sample will be targeted. Earlier recruitment efforts within the study demographic have resulted in majority female samples, consistent with prevalence rates within the study population. As such, recruitment efforts will be undertaken to ensure representation of male participants. Recruitment efforts will be taken to ensure adequate representation of underrepresented racial and ethnic minority groups.

Children between the ages of 13-17 will be included in this research as the program to be evaluated is specifically designed as an intervention for adolescents with symptoms of depression. Assent will be obtained from all children under 18 for study enrollment unless legally emancipated or financially independent in accordance with CA state regulations and regulations of the state in which the minor resides.

Study staff will monitor participants' symptom deterioration and questionnaire data for safety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
13 Years 至 21 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 13-21 years of age
  • PHQ-8 score ≥ 5 at eligibility screening
  • English fluency and literacy (participant and legal guardian, if applicable)
  • Access to a compatible smartphone (or other device) and operating system (i.e., capable of installing the app from the Google Play or Apple App Store; list will be provided on study website) and regular internet access
  • Participant willing and able to provide informed consent/assent and have legal guardian willing and able to provide informed consent (if required)
  • Under the care of a United States (U.S.)-based licensed healthcare provider and willing to provide contact information for the provider and sign a HIPAA release that allows Limbix to contact provider
  • Willing and able to provide information required for study enrollment (e.g. all responses to initial PHQ-8 assessment, and current antidepressant medication status)
  • Located in the continental U.S., Hawaii, or Alaska, and not planning to leave the U.S. during the study period (through 1-month follow up assessments, up to 11 weeks after eligibility screening)

排除标准

  • Diagnosis of (or treatment for) bipolar disorder, post traumatic stress disorder, psychotic disorder, substance use disorder, or eating disorder within the 12 months prior to eligibility screening
  • Change in psychotropic medication (initiation or change in dose) within the 30 days prior to eligibility screening
  • Plans to initiate or change treatment (e.g., psychotherapy, psychotropic medication, and/or other psychosocial treatment) for a mental health disorder during the study intervention period (5 weeks) as determined at eligibility screening
  • Suicide attempt within the past year
  • Active suicide ideation with intent
  • Previous participation in user testing or clinical testing of Spark or SparkRx, or other previous use of SparkRx app
  • Participation in any other clinical research involving a mental health intervention or treatment within 60 days prior to eligibility screening
  • Plans to participate in any other clinical research involving a mental health intervention or treatment during the study intervention period (5 weeks) as determined at eligibility screening
  • Any condition, comorbidity, or event that, in the opinion of the investigator, will prevent the participant from adhering to the protocol or benefitting from the intervention or will prevent investigators from being able to ensure safety
  • Having a sibling who is a past or current participant in the study

结局指标

主要结局

Depressive Symptom Severity at Post-intervention

时间窗: Post-intervention (5 week timepoint)

Measured by the Patient Health Questionnaire (PHQ-8), an 8-item participant-report measure for screening for depression and for establishing depression severity. The total score ranges from 0-24, with a higher score indicating greater depression symptom severity.

次要结局

  • Clinically-meaningful Reduction in Severity at Post-intervention(Change from baseline to post-intervention (5 weeks))
  • Intervention Response at Post-intervention(Change from baseline to post-intervention (5 weeks))
  • Remission at Post-intervention(Post-intervention (5 week timepoint))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验